Literature DB >> 24464609

Efficacy of 3D-positron emission tomography/computed tomography for upper abdomen.

Koji Murakami1, Tadaki Nakahara.   

Abstract

Recent advancement in computed tomography (CT) enables us to obtain high spatial resolution image and made it possible to construct extensive high-definition three-dimensional (3D) images. But a lack of contrast resolution in CT alone is still remained problem. Meanwhile, as fluorodeoxyglucose-positron emission tomography (PET) can visualize tumors in high contrast, we can create 3D images fusing the accumulation in tumors on PET/CT images. Such images can play the role of a "map of body" which makes it easy to understand the anatomical information before surgery. We also try to evaluate segmental liver function by using PET/CT fusion images. By using (11) C-methionine PET/contrast-enhanced CT, superior image quality compared to single photon emission computed tomography/CT can be obtained. CT, especially with contrast enhancement for obtaining anatomical imaging information plus PET for obtaining functional imaging information is a highly compatible combination, and adding these two types information will further increase clinical usefulness.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  11C-methionine; 3D reconstruction; Computed tomography angiography; Fusion image; Hepatic function; Positron emission tomography/computed tomography

Mesh:

Year:  2014        PMID: 24464609     DOI: 10.1002/jhbp.83

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  2 in total

1.  Impact of Three-Dimensional Surgical Simulation on Pancreatic Surgery.

Authors:  Ryoichi Miyamoto; Yukio Oshiro; Ken Nakayama; Nobuhiro Ohkohchi
Journal:  Gastrointest Tumors       Date:  2017-12-07

Review 2.  NIR-I Dye-Based Probe: A New Window for Bimodal Tumor Theranostics.

Authors:  Fan Zheng; Xueyan Huang; Jipeng Ding; Anyao Bi; Shifen Wang; Fei Chen; Wenbin Zeng
Journal:  Front Chem       Date:  2022-03-23       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.